Immatics Biotechnologies, a Germany-based kidney and anti-cancer drugs developer, has raised €53.8m ($75m), Europe’s largest venture round of the year and doubling the amount it has raised since its launch.
About half of the series C round came from Dievini Hopp Biotech, a local investment firm set up by a co-founder of Germany-based software company SAP, venture capital group Wellington Partners and other existing shareholders, including VC Vinci Capital’s Mona Lisa fund, which has Switzerland phone operator Swisscom as its sole limited partner.
The other half of the C round came from new investors MIG, which manages public venture capital funds, and AT Impf, the family office for brothers Andreas and Thomas Strüngmann.
In February 2007, Immatics raised €40m in its B round and more than €14m in its series A in 2004.